Imbria Pharmaceuticals, Inc. — Form D/A
Imbria Pharmaceuticals, Inc. of BOSTON, MA, a company, filed a Form D amendment with the SEC on 2025-12-16. The offering totals $144.2M, of which $66.7M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2025-12-16
- Form: D/A
- Accession: 0001104659-25-121539
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $144.2M
- Amount sold: $66.7M
- Remaining: $77.5M
- Investors: 10
- Date of first sale: 2025-03-10
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-542691
Issuer
- Name: Imbria Pharmaceuticals, Inc.
- CIK: 0001745672
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: 265 FRANKLIN STREET, BOSTON, MA, 02110
- Phone: 917-657-5069
Officers, directors & promoters (16)
| Name | Role | Location |
|---|
| Zina Affas Besse | Director | WOODLAND HILLS, CA |
| Pavan Cheruvu | Director | Boston, MA |
| Charles Dunn | Director | Boston, MA |
| Ken Horne | Director | Boston, MA |
| Andrew Levin | Director | BOSTON, MA |
| Luse Rebecca | Director | Boston, MA |
| Alvin Shih | Director | Boston, MA |
| Komal Joshi | Executive Officer | Boston, MA |
| Alvin Shih | Executive Officer | Boston, MA |
| Rebecca Luse | Director | Boston, MA |
| James Januzzi | Director | Boston, MA |
| Andrew C Levin | Director | Boston, MA |
| David-Alexandre C Gros | Director | Boston, MA |
| David-Alexandre C Gros | Executive Officer | Boston, MA |
| James C Januzzi | Director | Boston, MA |
| Pieter C Boelhouwer | Director | Rancho Santa Fe, CA |
Other filings by this issuer (3)
More